Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerated Diagnostic Pathways for Suspected Acute Coronary Syndrome in Practice: A Randomized Trial of 0/1-Hour vs 0/3-Hour Troponin Testing.

Journal of the American College of Cardiology·2026
Same author

Synthesis and biophysical evaluation of C-5-triazolyl-functionalized morpholino-thymidine analogs.

Organic & biomolecular chemistry·2026
Same author

Acyclic serinol nucleic acid modification of siRNAs overcomes seed region mediated off-target effects while maintaining potency.

Nucleic acids research·2026
Same author

Synthesis of siRNAs containing carbocyclic nucleotides and the role of cyclopentane conformation in RNAi activity.

RSC chemical biology·2026
Same author

Association of high-risk CT coronary artery plaque features with major adverse cardiovascular events: a prespecified secondary analysis of the DISCHARGE trial.

European radiology·2026
Same author

Occurrence and Ecotoxicological Risks of Pharmaceuticals and Illicit Drugs in Effluent and Unsheltered Homelessness-Impacted River Systems.

Archives of environmental contamination and toxicology·2026

Related Experiment Video

Updated: May 31, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.

Md Rowshon Alam1, Xin Ming, Michael Fisher

  • 1Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.

Bioconjugate Chemistry
|July 16, 2011
PubMed
Summary
This summary is machine-generated.

Chemically modified small interfering RNA (siRNA) conjugated to multivalent cyclic(arginine-glycine-aspartic) (cRGD) peptides effectively target and reduce luciferase expression in melanoma cells via receptor-mediated endocytosis.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

Related Experiment Videos

Last Updated: May 31, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Cancer Research

Background:

  • Integrin αvβ3 is a cell surface receptor overexpressed in various cancers, making it a target for drug delivery.
  • Small interfering RNA (siRNA) offers potential for gene silencing but requires effective delivery systems.
  • Cyclic(arginine-glycine-aspartic) (cRGD) peptides are known to bind specifically to integrin αvβ3.

Purpose of the Study:

  • To design, synthesize, and evaluate siRNA conjugates with multivalent cRGD peptides for targeted delivery to αvβ3-positive cancer cells.
  • To investigate the cellular uptake, intracellular distribution, and gene silencing efficacy of these cRGD-siRNA conjugates.
  • To compare the effects of bivalent, trivalent, and tetravalent cRGD conjugates on gene expression.

Main Methods:

  • Synthesis of chemically modified luciferase siRNA (Luc-siRNA) conjugated to bivalent, trivalent, and tetravalent cRGD peptides.
  • Utilizing M21(+) human melanoma cells, which stably express the luciferase reporter and αvβ3 integrin.
  • Assessing cellular uptake via fluorescence microscopy and measuring gene silencing by quantifying luciferase expression.
  • Analyzing subcellular localization of the conjugates using confocal microscopy.

Main Results:

  • cRGD-siRNA conjugates demonstrated receptor-mediated cellular uptake in M21(+) cells, unlike unconjugated siRNA.
  • The conjugates were internalized through a caveolar endocytotic pathway and localized to cytosolic vesicles.
  • Trivalent and tetravalent cRGD conjugates significantly reduced luciferase expression in a dose-dependent manner.
  • Bivalent cRGD conjugates showed minimal effect on luciferase expression, despite similar uptake levels.

Conclusions:

  • Multivalent cRGD peptide conjugation represents a selective and effective strategy for siRNA delivery to αvβ3-integrin-expressing cancer cells.
  • Trivalent and tetravalent cRGD conjugates exhibit superior gene silencing efficacy compared to bivalent conjugates.
  • This targeted delivery approach holds promise for further development in cancer therapy.